Meiji Seika Pharma Co. based out of Tokyo has decided to construct a new manufacturing facility at Adcock Ingram in Bangalore, India to enhance the production capacity of the contract manufacturing organization (CMO) business.

Adcock Ingram is a joint venture between Adcock Ingram Holdings, in South Africa, and Medreich Ltd., a wholly-owned subsidiary of Meiji Seika Pharma Co.

Adcock Ingram manufactures pharmaceutical products, by contract manufacturing, and distributes for the South African, European and Oceanian markets. By adding the new manufacturing facility, it can manufacture pharmaceutical products not only for the Adcock Ingram Group but also for other clients. The new manufacturing facility is built at a subsidiary of Adcock Ingram and is scheduled to start operation in March 2023.

The Meiji Group's Pharmaceutical Segment, in its "2023 Medium-Term Business Plan", has set an agenda to "Expand CMO/CDMO business" in its business strategies. We will continue to optimize our production bases in Japan and overseas to strengthen our production system and establish a system for the stable supply of highly reliable pharmaceuticals and contribute to improving access to pharmaceuticals for people over the world.

Overview of the new manufacturing facility